SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending as community members rally around the project's culture and real-world partnerships, including its sponsorship of a pro MMA fighter. The community is actively discussing the coin's potential and coordinated efforts to 'slap' the bears.

Fresenius Medical Care AG engages in the provision of products and services for individuals with renal diseases. It operates through the Care Enablement and Care Delivery segments. The Care Enablement segment is involved in the healthcare products business including research and development, manufacturing, supply chain, and commercial operations as well as supporting functions, such as regulatory and quality management. The Care Delivery segment focuses on the health care services for the treatment of CKD, ESRD, and other extracorporeal therapies, including value and risk-based care programs. The company was founded on August 5, 1996 and is headquartered in Bad Homburg, Germany.

Fresenius Medical Care AG - ADR

Fresenius Medical Care AG & Co. KGAA

Recent community interest in Fresenius Medical Care (FMS) stems from potential applications of DefenCath in dialysis and discussions around mortality benefits and infection prevention, particularly in comparison to competitors. Discussions also highlight an upcoming earnings report and its growth potential, with some suggesting it's undervalued, while others point to rising costs pressuring near-term results. Acquisition and partnership strategies are seemingly driving growth, but regulatory concerns persist in the dialysis and healthcare services sector.

Pop Cat refers to a series of videos in which using an image of a cat named Oatmeal, the cat is photoshopped as if it's opening its mouth wide in an O shape.

Popcat

POPCAT is trending as the community anticipates further gains, drawing comparisons to DOGE and SHIB, with some suggesting it could reach new all-time highs. Bullish sentiment is fueled by positive market vibes and accumulation, with predictions of a strong climb and some pointing to a potential test of resistance levels. Community members express optimism about the meme coin's potential within the Solana ecosystem, viewing it as a promising investment.

SSgA Active Trust - The Energy Select Sector SPDR Fund

Energy Select Sector SPDR Fund

The energy sector, represented by $XLE, is experiencing heightened volatility amidst geopolitical tensions and speculation around OPEC+ production decisions. Community discussions center on the potential for both short squeezes and longer-term gains, weighing factors like global demand, supply disruptions, and the impact of tariffs on the energy market. Traders are actively monitoring technical indicators and news events for directional cues, with some highlighting a possible rotation into energy amid broader market uncertainty.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending amid discussions around short-term bullish setups and potential targets, with community members actively debating entry points and whether recent price movements signal a continuation of its upward trend or a possible pullback. The coin is also tied into AI discussions, with community members exploring it's relationship with the emerging sector. Recent news of the coin being listed on a new exchange is potentially contributing to the increased interest.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is trending as investors assess if the semiconductor rally can continue, with some analysts pointing to overbought conditions and potential for a correction. Community members are debating the impact of AI spending, the potential for a chip glut, and revenue projections for chip manufacturers. Bullish sentiment remains due to the AI buildout, while others warn of bubble-like conditions reminiscent of the dot-com era.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as investors digest recent Q4 earnings forecasts and a planned workforce reduction, leading to price target cuts from analysts. The community is discussing potential bottom fishing opportunities, while also weighing the impact of macro headwinds and potential tariff implications. Despite concerns, some remain bullish on ON's long-term prospects in the EV and AI data center markets.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending due to positive momentum, fueled by strong revenue growth and optimism surrounding upcoming earnings, with the community discussing potential price targets and buyout scenarios. Community members are highlighting the company's solid fundamentals and pipeline, particularly Recorlev, while anticipating positive EPS. Bullish sentiment is driven by high growth expectations and potential upside from the XP-8121 program.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomm is trending amid discussions about its potential in the AI chip market and recent news regarding a possible antitrust probe in China, leading to community debate on its valuation and competitive positioning against Nvidia and AMD.  Bullish investors believe Qualcomm is undervalued and poised for growth in AI, pointing to its partnerships and low P/E ratio, while others express skepticism about its ability to compete effectively and highlight potential headwinds from regulatory issues and customer relationships. The community is closely watching for further developments in AI and potential catalysts.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products and services. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Quincy, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve is trending amid anticipation for potential cannabis rescheduling, spurred by comments from President Trump regarding a decision in the coming weeks. Community discussions revolve around the potential for significant gains, the impact on MSOs, and comparisons to Canadian LPs, while some caution against over-optimism. A potential Florida recreational vote in 2026 is also a key talking point for long term growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's Why

TD downgrades Milestone Pharmaceuticals, suspends target on Etripamil uncertainty

Investing.com -- TD Securities downgraded Milestone Pharmaceuticals (NASDAQ:MIST) to "Hold" and suspended its price target, citing regulatory uncertainty and commercialization challenges for its lead drug, etripamil, following a Complete Response Letter from the U.S. Food and Drug Administration.The FDA issued a Complete Response Letter for MIST’s etripamil New Drug Application for paroxysmal supraventricular tachycardia (pSVT), citing chemistry, manufacturing, and controls issues. While no safety or efficacy concerns were raised, the agency requested additional data on nitrosamine impurities based on new draft guidance published in September 2024, months after MIST had resubmitted its New Drug Application . The FDA also flagged the need for an inspection at a third-party facility performing release testing, which changed ownership during the New Drug Application review.

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/03/28/3051260/0/en/FDA-Issues-Complete-Response-Letter-for-Etripamil-for-PSVT.html">not approve</a> its lead investigational product, Cardamyst.The nasal spray is under development to treat episodes of abnormal heart rhythm associated with Paroxysmal supraventricular tachycardia (PSVT).The FDA highlighted two key Chemistry, Manufacturing and Controls (CMC) issues.The regulator asked the company to submit additional information on nitrosamine impurities based on the new draft guidance issued after the New Drug Application (NDA) submission. &nbsp;The agency also said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.Milestone Pharmaceuticals CEO Joe Oliveto said that the company is “deeply disappointed” by the letter but remains committed to the potential of the drug in treating patients with PSVT.“Our team is evaluating the feedback provided and intends to request a Type A meeting to discuss the issues raised in the CRL,” Oliveto said. “We are appreciative of the FDA’s efforts and are confident we can collaborate with the agency with the goal of addressing these issues in a resubmission.”The FDA did not raise any concerns regarding the drug’s clinical safety or efficacy, the company said.The nasal spray has been designed as a self-administered rapid response therapy, thereby bypassing the need for immediate medical oversight, it explained.On Stocktwits, retail investor sentiment about Milestone Pharmaceuticals dropped slightly within the ‘extremely bullish’ territory (89/100), while message volume remained at ‘extremely high’ levels over the past 24 hours.<figure class="image"><img style="aspect-ratio:652/152;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_28_at_12_10_06_PM_png_e7518f6d31.webp" alt="MIST's Sentiment Meter and Message Volume as of 12:10 p.m. ET on March 28, 2025 | Source: Stocktwits" width="652" height="152"><figcaption>MIST's Sentiment Meter and Message Volume as of 12:10 p.m. ET on March 28, 2025 | Source: Stocktwits</figcaption></figure>Following the company’s announcement, HC Wainwright kept a ‘Buy’ rating on Milestone pharmaceuticals and noted that the FDA flagged no concerns around the efficacy of the product, thereby reaffirming the integrity of the clinical data.However, the firm expects the product's launch to be delayed until the first half of 2026.<a href="https://stocktwits.com/symbol/MIST">Shares of Milestone Pharmaceuticals</a> fell over 55% this year and by over 45% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/hyperscale-data-shares-drop-despite-completing-first-nvidia-gpu-installation/chJ3iDORbEC">Hyperscale Data Stock Drops Despite Completing First Nvidia GPU Installation – But Retail Turns Bullish</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Milestone Pharmaceuticals Stock Plunges 60% After FDA Declines To Approve Its Cardamyst Nasal Spray – But Retail’s Positive 

The FDA said an inspection is required at a facility where the company performed release testing for the product to ensure it complies with Current Good Manufacturing Practices.

Equity

Milestone Pharmaceuticals Upgraded to Buy: Here's What You Should Know

Milestone Pharmaceuticals (NASDAQ: MIST) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings...

Milestone  Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference

MONTREAL and CHARLOTTE, N.C., April 03, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its management team will deliver a company...

Milestone  Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences

MONTREAL and CHARLOTTE, N.C., April 01, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of...

Milestone's Etripamil Aims to Revolutionize PSVT Treatment

Milestone Pharmaceuticals (MIST) has released an update. Milestone Pharmaceuticals has announced the resubmission of its New Drug Application to th...

Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia

MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of...

Milestone Pharmaceuticals (NASDAQ:MIST) Stock Rating Reaffirmed by HC Wainwright

Milestone Pharmaceuticals (NASDAQ:MIST  Get Free Report)s stock had its buy rating restated by research analysts at HC Wainwright in a research note issued on Friday...

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update

- On track to resubmit NDA for etripamil in PSVT early 2Q 2024 - Recent financing extends cash runway into 2026 - FDA reiterated prior guidance on regulatory pathway for AFib-RVR, End of Phase 2...

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. Its lead product candidate etripamil, is a novel, potent and short-acting calcium channel blocker that is designed as a rapid-onset nasal spray to be self-administered by patients. It develops etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, rapid ventricular rate, and other cardiovascular indications. The company was founded by Philippe Douville and Philippe Lamarre in 2003 and is headquartered in Montreal, Canada.

Milestone Pharmaceuticals Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

MIST
Milestone Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MIST News

MISTMilestone Pharmaceuticals Inc